New Breast Cancer Drug
Extends Lives Unprecedentedly
September 28, 2014 -
New breast cancer treatment has
appeared on the market with good results as never before, experts
A new drug against metastatic breast cancer
called Perjeta (Pertuzumab), from the Roche Company,
seems to prolong life in women with
advanced breast cancer, a new study has revealed.
The experts of this study encourage its utilization to
help women around the world in their fight against the disease. Designed specifically to target and treat
metastatic breast cancer, Perjeta follows Herceptin,
with which it can be combined with and
associated with chemotherapy.
Perjeta, which was approved by the FDA
authorities after it was tested in the Roche-backed study of over 800 women
with cancer of the breast, is now considered as one of the best
breast cancer drug on the market.
According to researchers, women who were diagnosed with
breast cancer HER2 positive
who received Perjeta in
addition of the drug Herceptin (trastuzumab) and chemotherapy lived more
than 15 months longer than those
who were treated with
Herceptin and chemotherapy alone.
This is important news because
HER2 positive represents about a
quarter of all breast cancers. Both Perjeta and Herceptin are antibodies designed to block
the function of HER2, a protein produced by a cancer-related gene.
We have never recorded such an extension
of life in any drug study
in metastatic breast cancer before, the experts say. The
medication has the property to stop the disease from
spreading to other parts of the body over a long period of
time. The result confirms the importance of
combining medications to better fight tumor cells in a variety of ways. Many experts say they are delighted
and consider Perjeta as a
This new treatment is produced by the Roche pharmaceutical company; it helps fighting against an aggressive form of breast cancer.
Perjeta, also called Pertuzumab is
a drug designed for women with
metastatic, HER2-positive breast cancer, and
have not yet received any treatment in
combination with Herceptin or docetaxel
before, said the specialists of Roche, the Swiss
pharmaceutical company, in a statement. This new breast cancer drug has provided
hope for women HER2-positive breast as never before.
Among the most daunting forms of cancer,
HER2-positive is one of the top, which is
distinguished by its aggressiveness. HER2 (Human Epidermal Growth Factor
Receptor 2) is a receptor normally presents on the membrane
of many cells, and regulates
growth and proliferation.
When the number of HER2 increases
abnormally, it then leads to
uncontrolled cell growth which may
be malignant. Approximately 20-25% of breast cancers are HER2-positive
and have a faster progression
characteristic. Most women with this form of
breast cancer are between 30 and 45 years. They have negative response to
drug treatment, and in general,
a negative prognosis.
Breast Cancer Patients
The pharmaceutical group Roche
had already put on the market about a decade ago a new specific treatment for this
form of breast cancer, Herceptin, which
has enabled, in conjunction with chemotherapy , to extend the duration of a few
months of life for many patients with advanced forms of advanced breast cancer. But this new cancer treatment
will also permit more healing for patients in early stages of this form of
pharmaceutical company has a new
compound in the fight against breast
cancer, Perjeta (Pertuzumab), which has very promising
medical properties, reported the group. The Swiss company
said that patients treated with
combined therapy Perjeta
to live about 15.5 months longer, compared to patients treated with Herceptin alone, even
if it is in combination with
chemotherapy. The association with Perjeta reduces
risk of death significantly.
This new breast cancer treatment is the most
important progress in the treatment of aggressive forms breast malignancies,
since the marketing of
Herceptin. Today, the future of breast cancer treatment and the possibility
of survival is more than a promise, it becomes a
reality, they experts say.